Johnson & Johnson (JNJ) is an interesting player in the Healthcare space, with a focus on Drug Manufacturers – Major. The stock has been active on the tape, currently trading at $123.85, down from yesterday’s close by -1.20%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.Fundamental Analysis
Johnson & Johnson (JNJ) currently trades with a market capitalization of $332.19 Billion. That value represents a market adjusting for revenues that have been growing by 12.63 % on a quarterly year/year basis as of the company’s last quarterly report.
You can get a sense of how sustainable that is by a levered free cash flow of $18.38 Billion over the past twelve months. Generally speaking, earnings are expected to fall in coming quarters. Analysts are forecasting earnings of $2.07 on a per share basis this quarter. Perhaps, that suggests something about why 0.12% of the outstanding share supply is held by institutional investors.
It’s important to check the technicals to get a sense of how JNJ has been acting. Looking at the stock’s movement on the chart, Johnson & Johnson recorded a 52-week high of $148.32. It is now trading 24.47% off that level. The stock is trading $128.12 its 50-day moving average by 4.27%. The stock carved out a 52-week low down at $121.28.
In recent action, Johnson & Johnson (JNJ) has made a move of -2.90% over the past month, which has come on weak relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 15.08, and it’s gotten there by action that has been less volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 0.71% with $2.68 Billion sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of JNJ.